Cargando…

Clinical applications of PD-L1 bioassays for cancer immunotherapy

Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression as a biomarker of response have been developed for many cancer immunotherapy agents. Thes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Delong, Wang, Shuhang, Bindeman, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436438/ https://www.ncbi.nlm.nih.gov/pubmed/28514966 http://dx.doi.org/10.1186/s13045-017-0479-y

Ejemplares similares

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
por: Liu, Bingshan, et al.
Publicado: (2017)

Adenovirotherapy delivering cross-hybrid IgGA Fc engineering PD-L1 inhibitors for enhanced cancer immunotherapy
por: Zhao, Guo, et al.
Publicado: (2023)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
por: Ayala-Mar, Sergio, et al.
Publicado: (2021)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

PD-L1 degradation pathway and immunotherapy for cancer
por: Gou, Qian, et al.
Publicado: (2020)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
por: Pei, Liping, et al.
Publicado: (2023)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
por: Abdin, Shifaa M., et al.
Publicado: (2018)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
por: Wakabayashi, Grace, et al.
Publicado: (2019)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Yin, Zi, et al.
Publicado: (2021)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
por: Cai, Jiajing, et al.
Publicado: (2019)

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
por: Jiang, Wenxiao, et al.
Publicado: (2021)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
por: Ren, Yifan, et al.
Publicado: (2022)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
por: Jia, Long, et al.
Publicado: (2018)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
por: Kong, Xianbin, et al.
Publicado: (2021)

The role of exosomal PD-L1 in tumor progression and immunotherapy
por: Xie, Feiting, et al.
Publicado: (2019)

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
por: Wang, Jun, et al.
Publicado: (2017)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020)

The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
por: Chen, Ke, et al.
Publicado: (2021)

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
por: Strati, Areti, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bclc7b52frbfk2jjb83tvfm625